These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1360 related articles for article (PubMed ID: 28943491)

  • 1. Comparison of Endovascular Versus Bypass Surgery in Femoropopliteal TASC II D Lesions: A Single-Center Study.
    Veraldi GF; Mezzetto L; Macrì M; Criscenti P; Corvasce A; Poli R
    Ann Vasc Surg; 2018 Feb; 47():179-187. PubMed ID: 28943491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized comparison of ePTFE/nitinol self-expanding stent graft vs prosthetic femoral-popliteal bypass in the treatment of superficial femoral artery occlusive disease.
    McQuade K; Gable D; Hohman S; Pearl G; Theune B
    J Vasc Surg; 2009 Jan; 49(1):109-15, 116.e1-9; discussion 116. PubMed ID: 19028055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heparin-bonded covered stents versus bare-metal stents for complex femoropopliteal artery lesions: the randomized VIASTAR trial (Viabahn endoprosthesis with PROPATEN bioactive surface [VIA] versus bare nitinol stent in the treatment of long lesions in superficial femoral artery occlusive disease).
    Lammer J; Zeller T; Hausegger KA; Schaefer PJ; Gschwendtner M; Mueller-Huelsbeck S; Rand T; Funovics M; Wolf F; Rastan A; Gschwandtner M; Puchner S; Ristl R; Schoder M
    J Am Coll Cardiol; 2013 Oct; 62(15):1320-7. PubMed ID: 23831445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stenting vs above knee polytetrafluoroethylene bypass for TransAtlantic Inter-Society Consensus-II C and D superficial femoral artery disease.
    Dosluoglu HH; Cherr GS; Lall P; Harris LM; Dryjski ML
    J Vasc Surg; 2008 Nov; 48(5):1166-74. PubMed ID: 18692357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Four-year randomized prospective comparison of percutaneous ePTFE/nitinol self-expanding stent graft versus prosthetic femoral-popliteal bypass in the treatment of superficial femoral artery occlusive disease.
    McQuade K; Gable D; Pearl G; Theune B; Black S
    J Vasc Surg; 2010 Sep; 52(3):584-90; discussion 590-1, 591.e1-591.e7. PubMed ID: 20598480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heparin-bonded expanded polytetrafluoroethylene femoropopliteal bypass grafts outperform expanded polytetrafluoroethylene grafts without heparin in a long-term comparison.
    Samson RH; Morales R; Showalter DP; Lepore MR; Nair DG
    J Vasc Surg; 2016 Sep; 64(3):638-47. PubMed ID: 27139782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of polytetrafluoroethylene-covered stent versus bare-metal stent in the primary treatment of severe iliac artery obstructive lesions.
    Piazza M; Squizzato F; Spolverato G; Milan L; Bonvini S; Menegolo M; Grego F; Antonello M
    J Vasc Surg; 2015 Nov; 62(5):1210-8.e1. PubMed ID: 26254822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of antiplatelet/anticoagulation regimens after Viabahn stent graft treatment for femoropopliteal occlusive disease.
    Ullery BW; Tran K; Itoga N; Casey K; Dalman RL; Lee JT
    J Vasc Surg; 2015 Jun; 61(6):1479-88. PubMed ID: 25704407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mid-Term Outcomes of Endovascular Treatment for TASC-II D Femoropopliteal Occlusive Disease with Critical Limb Ischemia.
    Torres-Blanco Á; Edo-Fleta G; Gómez-Palonés F; Molina-Nácher V; Ortiz-Monzón E
    Cardiovasc Intervent Radiol; 2016 Mar; 39(3):344-52. PubMed ID: 26202389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Late outcomes of balloon angioplasty and angioplasty with selective stenting for superficial femoral-popliteal disease are equivalent.
    Nguyen BN; Conrad MF; Guest JM; Hackney L; Patel VI; Kwolek CJ; Cambria RP
    J Vasc Surg; 2011 Oct; 54(4):1051-1057.e1. PubMed ID: 21636240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of the standard bolia technique versus subintimal recanalization plus Viabahn stent graft in the management of femoro-popliteal occlusions.
    Boufi M; Dona B; Orsini B; Auquier P; Hartung O; Alimi YS
    J Vasc Surg; 2010 Nov; 52(5):1211-7. PubMed ID: 20692789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes of endovascular treatment of TASC-II C and D femoropopliteal lesions with the Viabahn endoprosthesis.
    Mohr PJ; Oyama JK; Luu JT; Stinis CT
    Cardiovasc Revasc Med; 2015 Dec; 16(8):465-8. PubMed ID: 26483319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contemporary outcomes after superficial femoral artery angioplasty and stenting: the influence of TASC classification and runoff score.
    Ihnat DM; Duong ST; Taylor ZC; Leon LR; Mills JL; Goshima KR; Echeverri JA; Arslan B
    J Vasc Surg; 2008 May; 47(5):967-74. PubMed ID: 18372147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results for primary bypass versus primary angioplasty/stent for lower extremity chronic limb-threatening ischemia.
    Darling JD; McCallum JC; Soden PA; Korepta L; Guzman RJ; Wyers MC; Hamdan AD; Schermerhorn ML
    J Vasc Surg; 2017 Aug; 66(2):466-475. PubMed ID: 28274753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of infrainguinal revascularization with bypass surgery using a heparin-bonded graft for disabling intermittent claudication due to femoropopliteal occlusive disease.
    Piffaretti G; Dorigo W; Ottavi P; Pulli R; Castelli P; Pratesi C;
    J Vasc Surg; 2019 Jul; 70(1):166-174.e1. PubMed ID: 31113719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 1-Year Results of a Multicenter Randomized Controlled Trial Comparing Heparin-Bonded Endoluminal to Femoropopliteal Bypass.
    Reijnen MMPJ; van Walraven LA; Fritschy WM; Lensvelt MMA; Zeebregts CJ; Lemson MS; Wikkeling ORM; Smeets L; Holewijn S
    JACC Cardiovasc Interv; 2017 Nov; 10(22):2320-2331. PubMed ID: 29169500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iliac Artery Stenting Combined with Ipsilateral Open Femoro-Popliteal Revascularization and Its Effect on Bypass Patency.
    Piazza M; Squizzato F; Lepidi S; Menegolo M; Grego F; Antonello M
    Ann Vasc Surg; 2017 Oct; 44():282-288. PubMed ID: 28479462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heparin-bonded stent-graft for the treatment of TASC II C and D femoropopliteal lesions: the Viabahn-25 cm trial.
    Zeller T; Peeters P; Bosiers M; Lammer J; Brechtel K; Scheinert D; Rastan A; Noory E; Beschorner U
    J Endovasc Ther; 2014 Dec; 21(6):765-74. PubMed ID: 25453876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of intravascular ultrasound in femoropopliteal stenting for peripheral artery disease with TASC II class A to C lesions.
    Iida O; Takahara M; Soga Y; Suzuki K; Hirano K; Kawasaki D; Shintani Y; Suematsu N; Yamaoka T; Nanto S; Uematsu M
    J Endovasc Ther; 2014 Aug; 21(4):485-92. PubMed ID: 25101575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ZILVERPASS Study: ZILVER PTX Stent vs Bypass Surgery in Femoropopliteal Lesions.
    Bosiers M; Setacci C; De Donato G; Torsello G; Silveira PG; Deloose K; Scheinert D; Veroux P; Hendriks J; Maene L; Keirse K; Navarro T; Callaert J; Eckstein HH; Teβarek J; Giaquinta A; Wauters J
    J Endovasc Ther; 2020 Apr; 27(2):287-295. PubMed ID: 31997715
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 68.